Bruno Constantino Alexandre Dos Santos, Director, on September 16, 2026, sold 123,257 shares in XP (XP) for $2,413,865. Following the Form 4 filing with the SEC, Dos Santos has control over a total of 1,500,000 Class A common shares of the company, with 1,500,000 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1787425/000095010326014163/xslF345X05/ownership.xml
Jon Faiz Kayyem, Director, on September 16, 2026, executed a purchase for 5,000 shares in Inhibrx Biosciences (INBX) for $500,000. Following the Form 4 filing with the SEC, Kayyem has control over a total of 1,069,046 common shares of the company, with 1,069,046 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2007919/000136626826000006/xslF345X05/wk-form4_1789681608.xml
Paul Cunningham, Senior Vice President, on September 15, 2026, sold 2,000 shares in Cadence Design Systems (CDNS) for $554,240. Following the Form 4 filing with the SEC, Cunningham has control over a total of 121,793 common shares of the company, with 121,793 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/813672/000081367226000100/xslF345X05/wk-form4_1789681310.xml
John Kenneweg, Senior Vice President, Sales & Product Marketing, on September 15, 2026, sold 27,656 shares in 908 Devices (MASS) for $280,070. Following the Form 4 filing with the SEC, Kenneweg has control over a total of 57,784 common shares of the company, with 57,784 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1555279/000183687626000011/xslF345X05/form4-09172026_090941.xml